CapitalBio Corporation to Offer Genotyping Services Using Affymetrix 500K Array in China; Company Earns Affymetrix Service Prov
28 July 2006 - 10:00AM
Business Wire
Affymetrix Inc., (Nasdaq:AFFX) and CapitalBio Corporation, a
leading life science company based in Beijing, P.R. China,
announced today that CapitalBio has become a certified Affymetrix
Service Provider and will begin offering genotyping services using
the Affymetrix GeneChip(R) Human Mapping 500K Array Set. The 500K
Array enables researchers to search across the entire genome in
detail to find genes involved in disease or drug response.
CapitalBio has been offering gene expression profiling services
using Affymetrix microarray technology for more than a year. The
two companies have also been working together on joint R&D and
commercialization programs, including the development of an
advanced GeneChip-compatible personal scanner. "The gene expression
and genotyping market are gaining momentum as more and more
international pharmaceutical companies out-source microarray
services in China and more and more Chinese scientists employ
microarrays to solve biological problems," said David Sun, senior
vice president, Business Development and Marketing at CapitalBio.
"As a Certified Affymetrix Service Provider, CapitalBio can now
provide broader high quality microarray based services beyond its
already extensive products and services to gain information at
gene, protein, cell and tissue levels to address the increasing
needs of global customers." "CapitalBio has been offering
microarray services using Affymetrix technology for more than a
year and has demonstrated its ability to provide quality services
using 500K arrays," said Wei Zhou, vice president and country
manager of China at Affymetrix. "Affymetrix is committed to
enabling the Chinese scientific community to access to all of the
statistical power in the Affymetrix genotyping arrays to gain a
better understanding of the genetic causes of complex disease."
About CapitalBio CapitalBio is a leading life science Company that
develops and commercializes a broad range of products, including
Biochip technology products, for drug discovery research, genomics,
proteomics, bio-safety testing and clinical applications.
Headquartered in Beijing, China, CapitalBio has rapidly evolved
from a young innovative biochip developer into a comprehensive life
science entity with five affiliates or subsidiaries: AVIVA
Biosciences, a San Diego, California based company that develops
and markets on-chip patch-clamp technologies for ion-channel
studies for drug discovery researches; Chipscreen Biosciences, a
Biotech company located in Shenzhen, China, for small molecular
drug discovery and development; and CapitalBio International and
CapitalBio Hong Kong, two fully owned subsidiaries by CapitalBio
Corporation, are based at San Diego, California and Hong Kong,
China respectively. Additional information on CapitalBio can be
found at www.capitalbio.com. About Affymetrix Affymetrix scientists
invented the world's first high-density microarray in 1989 and
began selling the first commercial microarray in 1994. Since then,
Affymetrix GeneChip(R) technology has become the industry standard
in molecular biology research. Affymetrix technology is used by the
world's top pharmaceutical, diagnostic and biotechnology companies
as well as leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and nearly 4,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: uncertainties
relating to the genotyping services that CapitalBio will offer,
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc. CapitalBio,
and the CapitalBio logo, and Capital Biochip are registered
trademarks owned or used by CapitalBio Corporation. AVIVA,
Chipscreen are registered trademarks owned or used by AVIVA
Biosciences and Chipscreen Biosciences respectively.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024